A range of new diagnostic tests – clinical measures that guide how patients are treated – have been developed by Abbott Laboratories, promising to cut costs and more efficiently manage outcomes.
According to an April 1 press release from Abbott, nearly three-quarters of medical decisions are at least partially determined by diagnostic screening, such as those facilitated by the company’s new Alinity line of diagnostic tests.
Alinity encompasses tests for a variety of conditions, looking for disease indications via immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics, the release said.
Dennis Gilbert, Abbott’s vice president for research and development in the diagnostics division, said the new line of testing supplies and instruments will save time and make it easier to deliver critical care.
"To design AlinIQ and the Alinity Systems, we spent countless hours with our customers in the design phase to ensure that we built solutions for the issues they face every day – including higher testing volumes, a lack of staffing and space, and complex, time-intensive processes and instruments," Gilbert said in the release.
The Alinity line was rolled out last year, and new products are slated to be added through 2018.
